Buy Osphos Online
Osphos Injectable syndrome is a multifaceted disease and the treatment options are not always clear.
- When radiographic signs indicative of bony changes associated with navicular syndrome are present, OSPHOS is a clear choice.
What is Osphos?
- Injectable bisphosphonate solution for the control of clinical signs associated with navicular syndrome
- OSPHOS inhibits bone resorption by binding to calcium phosphate crystals (inhibiting their formation and dissolution), and by exerting direct cellular effects on osteoclasts.
- It is supplied as 15 mL (900 mg) of clodronate disodium (60 mg/mL) per vial and is ready-to-use (no reconstitution or dilution required).
OSPHOS Injection (Canada)
This page contains information on OSPHOS Injection for veterinary use.
The information provided typically includes the following:
- OSPHOS Injection Indications
- Warnings and cautions for OSPHOS Injection
- Direction and dosage information for OSPHOS Injection
OSPHOS Injection
This treatment applies to the following species:
Company: DechraClodronate disodium injection, 60 mg/mL
STERILE
DIN 02440776
Veterinary Use Only
THERAPEUTIC CLASSIFICATION: Bisphosphonate
Description
Clodronate disodium is a non-amino, chloro-containing bisphosphonate. Chemically, clodronate disodium is (dichloromethylene) diphosphonic acid disodium salt and is manufactured from the tetrahydrate form.
Active Ingredients
Each mL contains 60 mg clodronate disodium (as clodronate disodium tetrahydrate), EP. Contains no preservatives.
OSPHOS Injection Indications
For the control of clinical signs associated with navicular syndrome in horses.
Dosage and Administration
Administer by intramuscular injection. Divide the total volume of OSPHOS Injection to be administered evenly into three (3) separate injection sites.The recommended dose is 1.8 mg clodronate disodium/kg body weight (3 mL per 100 kg body weight) up to a maximum dose of 900 mg (15 mL) per horse.
Clinical improvement is most evident at 2 months post-treatment (see EFFICACY).
Contraindications
– Do not use OPSHOS Injection in horses with known hypersensitivity to clodronate disodium.
– Do not use this product in horses with impaired renal function or with a history of renal disease.
CAUTIONS:
Warnings
– Keep out of reach of children.
– Not for use in horses that are to be slaughtered for use in food.
self-injection, consult a physician immediately.
– Avoid contact with skin or eyes. Accidental spillage on the skin or eyes should be washed off with water.
Adverse Reactions
Overview:
In horses treated with the recommended dose of OSPHOS Injection, these clinical signs (see Tables 1 and 4) usually began within 2 hours of treatment.
Field trial data:
One horse experiencing colic and hives required treatment with flunixin and dexamethasone to resolve clinical signs. In 8 of the 10 horses, 10 to 15 minutes of hand walking resulted in resolution of clinical signs. In one horse, clinical signs resolved without hand walking. Three additional horses experienced lip licking, yawning, and/or head shaking.
Reviews
There are no reviews yet.